Biotech Values

[poorgradstudent]

ARIA etc...

>Does this raise a red-flag on Bosutinib?<

I think I should clarify that I'm not so much as afraid of bosutinib as concerned about the speed at which ariad can bring their drug to earlier treatment stages.

My pie-in-the-sky dream is that the next trial ARIA starts tomorrow is a head to head trial against imatinib / nilotinib / dasatinib (investigator's choice) in T315I mutation bearers only.

That could reasonably get ponatinib up to a part of the first line, and then ariad could have a reasonable claim with docs that if they don't have a mutation status report on their patients that they're better off starting them all on ponatinib.